MT-4129-E01
57 evidence topics · 4 sources
Objective
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses
“This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of lorundrostat in healthy adult participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This first‐in‐human dose escalation study evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple oral doses of lorundrostat, a highly selective CYP11B2 inhibitor. In addition, this study also compared lorundrostat PK in females and males and older adult (≥65 years old) and younger adult participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered purpose and official title
Concentration-QTc evaluation within the first-in-human study
Location and study date
Single center in the Netherlands, November 2016 to May 2017
Registered site, sponsor, and dates
| Field | Quoted record |
|---|---|
| Location | “Pharmaceutical Research Associates (PRA) Health Sciences” |
| Sponsor | “Tanabe Pharma Corporation” |
| Other study ID number | “MT-4129-E01” |
| Study start | “2016-11” |
| Primary completion (actual) | “2017-05” |
| Study completion (actual) | “2017-05” |
Ethics approval and contract research organization
“The study was approved by the local independent ethics committee; the BEBO foundation in Assen, Netherlands; and the Central Committee on Research Involving Human Subjects in The Hague, Netherlands; and conducted according to the provisions of the Declaration of Helsinki.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thijs van Iersel and Jan Jaap van Lier are employees of ICON, the CRO which conducted the clinical study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Four-part, randomized, double-blind, placebo-controlled design
“A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017) to determine the safety, tolerability, PK, and PD of single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants (EudraCT Number: 2016–003500‐32).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study also assessed sex‐ (part 3) and age‐related (part 4) effects on the PK of a single dose of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory food comparison
“An exploratory comparison of the effect of food on PK profiles of lorundrostat was also performed by assessing single‐dose PK profiles of lorundrostat in the fasted state (part 1) vs. PK profiles of lorundrostat in the fed state (part 2 after the first‐dose administered).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sentinel dosing and dose escalation rules
“All cohorts included two sentinel participants of whom one received lorundrostat and one received matching placebo. The remaining six participants, of whom five received lorundrostat and one received placebo, were dosed ≥24 h later.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Doses were administered in an ascending order per cohort. After each cohort, all safety data were reviewed prior to initiating the next dose cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Progression to the next dose level was based on available data from part 1 and the preceding dose cohort in part 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered design details
| Field | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
| Primary purpose | “Other” |
Holter electrocardiograms matched to pharmacokinetic sampling
Eligibility criteria
Healthy Caucasian men, women, and older men
“Healthy male Caucasian participants (parts 1 and 2) aged 18–55 years (inclusive), healthy non‐pregnant and non‐lactating female Caucasian participants (part 3) aged 18–55 years (inclusive), and healthy male Caucasian participants aged ≥65 years (part 4) were eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered inclusion and exclusion criteria
Treatment
Part 1: single ascending doses of 5 to 800 mg, fasted
“In part 1, in each dose cohort, six participants were randomized to receive a single dose of lorundrostat and two participants were randomized to receive matching placebo in the fasted state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dosing cohorts were 5, 10, 20, 50, 100, 200, 400, and 800 mg (5‐mg starting dose rationale provided in Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 2: once-daily doses of 40, 120, or 360 mg for 7 days, fed
“In part 2, in each cohort, nine participants received daily doses of lorundrostat and three participants received matching placebo in the fed state from Day 1 to Day 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The final dose levels of lorundrostat for part 2 were 40, 120, and 360 mg. An adrenocorticotropic hormone (ACTH) challenge test was performed on Day ‐2 and Day 6 to evaluate the lorundrostat selectivity for aldosterone synthesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parts 3 and 4: single 100 mg dose in women and in men aged 65 years or older
“In one cohort of eight females (part 3) and one cohort of eight males aged ≥65 years (part 4), six participants were randomized to receive a single 100‐mg dose of lorundrostat and two participants were randomized to receive matching placebo in the fasted state in each part. The results were compared with those at the same dose in part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capsule formulation relative to the phase 2 tablet
“The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study (doses used in the phase II study included 12.5 mg once daily and twice daily, 25 mg twice daily, 50 mg once daily, and 100 mg once daily).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using adverse events as the primary endpoint
Registered primary outcome measures
Safety assessments in the publication
“Safety assessments included treatment‐emergent adverse events (TEAEs), treatment‐related TEAEs, vital signs, 12‐lead electrocardiograms (ECGs), clinical laboratory evaluations, and physical examinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Purpose of phase 1 studies in federal regulation
Rationale for cortisol and ACTH-stimulation safety assessments
“CYP11B1, a key enzyme in glucocorticoid biosynthesis, has a high homology to CYP11B2 (>93%). High selectivity for CYP11B2 over CYP11B1 is an essential characteristic for a successful aldosterone synthase inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Osilodrostat, the first aldosterone synthase inhibitor, lacked high selectivity, resulted in blunted adrenocorticotropic hormone‐stimulated cortisol release in some patients, and instead became a treatment for Cushing's disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the concentration-QTc analysis
Registered secondary pharmacokinetic and pharmacodynamic outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Participants screened and randomized
“A total of 245 participants were screened, of which 116 were randomized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Field | Quoted record |
|---|---|
| Enrollment (estimated) | “116” |
Participants per part
“Part 1 (SAD) included 64 male participants between 18 and 55 years old. Part 2 (MAD) included 36 male participants between 19 and 54 years of age. Part 3 (sex effect) included eight female participants between 20 and 35 years of age. Part 4 (age effect) included eight male participants between 68 and 80 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants in the concentration-QTc analysis groups
Description of analysis sets
Safety, pharmacokinetic, and pharmacodynamic analysis sets
“Safety analyses used the safety analysis set (all participants who received at least one dose of study drug).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All PK analyses used the PK analysis set (all participants who received at least one dose of study drug other than placebo and had PK data considered sufficient and interpretable).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All PD analyses used the PD analysis set (all participants who received at least one dose of study drug, had at least one post‐dose PD assessment, and PD data considered sufficient and interpretable).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose proportionality, sex, age, and food comparisons
“Dose proportionality was concluded if the 95% confidence interval (CI) for slope (β) included the value 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Difference in least square means and corresponding 90% CI were back‐transformed to obtain the estimates of geometric mean ratios and their CI for females vs. males and participants ≥ 65 years old vs. 18–55 years old. The result was judged to be statistically significant if the 90% CI did not include 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No formal statistical comparison was performed for an exploratory comparison of PK between fasted (part 1) and fed (part 2, after the first‐dose administered) states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic and QTc analysis set
Results
Participant disposition
Withdrawal for sinus tachycardia in the 360 mg cohort
“One participant in cohort 3 of part 2 was withdrawn on Day 2 because of an AE of sinus tachycardia (117 bpm) before dosing on Day 2, and he received only one dose of 360 mg lorundrostat on Day 1 (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics by dose group and part
Efficacy results
In vitro selectivity for CYP11B2 over CYP11B1
“Lorundrostat inhibited hCYP11B2 and hCYP11B1 with inhibition constant values of 1.27 nmol/L and 475 nmol/L, respectively. These results indicate that lorundrostat inhibits CYP11B2 with 374‐fold selectivity over CYP11B1 (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-dose pharmacokinetics
“Following single oral doses across 5–800 mg, plasma drug concentration–time profiles demonstrated rapid absorption with a median time to maximum concentration (T max) 1.0–1.5 h (Table 3; Figure 1b); the mean terminal half‐life (t 1/2) ranged from 7.9 to 10.5 h, and apparent clearance was comparable, ranging from 18.7 to 27.6 L/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the estimate of the slope (95% CI) for C max versus dose was 1.104 (1.043–1.164), and a slightly greater than dose proportional increase in C max was observed over the range 5–800 mg (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiple-dose pharmacokinetics and accumulation
“A steady state was achieved by approximately Day 5 and very slight accumulation of lorundrostat was observed following multiple dosing compared with Day 1, with the mean rate of accumulation values for AUC0–24 ranging from 1.15 to 1.19 across the entire dose range. Consistent with single‐dose administration, the mean t 1/2 values on Day 7 ranged from 9.1 to 11.9 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma pharmacokinetic parameters by dose
Urinary excretion of unchanged drug and renal clearance
“After a single dose of 40–360 mg of lorundrostat on Day 1, the fraction of the dose excreted in the urine as unchanged was low, with mean values ranging between 1.2%–1.8%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%. The fraction of the lorundrostat dose excreted remained consistent over the multiple‐dose range tested. Renal clearance was low and generally similar across all multiple‐dose levels (mean CLR ranging between 0.4 and 0.6 L/h on Day 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effects of sex, age, and food on pharmacokinetics
“In part 3 of the study, after a single 100‐mg dose of lorundrostat, there was no statistically significant difference between lorundrostat exposure in females and males (Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In part 4, there was no statistically significant difference between older adult and younger adult lorundrostat exposures (Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the dose escalation data of the first cohort in part 2 where lorundrostat was administered in the fed state, the PK profile did not appear to be affected compared with part 1 where lorundrostat was administered in the fasted state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma aldosterone suppression after single doses
“At the lower dose levels (lorundrostat 5–50 mg), the PAC returned to values near baseline within 24 h post‐dose. At the higher dose levels (lorundrostat 100–800 mg), the reduction of PAC was sustained until 24 h post‐dose. PAC showed maximum decreases at 4 h and 8 h post‐dose of ~80% compared with placebo. Single doses of lorundrostat, ranging from 10 to 800 mg reduced the AUC0–24 for PAC in a dose‐dependent manner, with statistically significant decreases ranging from 36% to 77% vs. placebo (Figure 2b; Table S5) without effecting cortisol (Figure 2c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone after multiple doses and rebound after the last dose
“Consistent with the SAD cohorts, multiple‐dose lorundrostat data demonstrated that for all dose levels tested, PAC decreased in an apparent dose‐dependent manner between 2 and 12 h post‐dose on Day 7 (Figure 2d). From 24 h after the last dose on Day 7, a clear rebound in PAC ranging from 73% to 163% compared with placebo was observed at all multiple‐dose levels of lorundrostat. These increases were sustained at least until Day 10, 3 days after the last dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ACTH-stimulated aldosterone and cortisol
“During non‐ACTH challenge conditions, no relevant changes from baseline were observed for serum cortisol concentrations and plasma 11‐deoxycortisol concentrations during multiple dosing of lorundrostat. At all multiple‐dose levels, lorundrostat completely blunted the ACTH‐stimulated aldosterone response on Day 6 compared with placebo, while there was no effect on the cortisol response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renin activity, 11-deoxycorticosterone, and urinary sodium
“Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d). In the MAD, the urine sodium and urinary log10 (10 × Na+/K+) ratio was initially increased on Day 1 at all dose levels, but the ratio returned to baseline levels at the next sampling timepoint at the end of the dosing period on Day 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Implications for dose selection
“Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Serious and overall treatment-emergent adverse events
“Lorundrostat was well tolerated and no serious TEAEs occurred during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]). Across all cohorts, dizziness (of mild intensity) was reported by nine (10.3%) lorundrostat‐treated participants compared with one (3.4%) placebo‐treated participant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no clinically significant findings with respect to clinical laboratory, vital signs, ECGs, or physical examination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events after single doses
Treatment-related adverse events after multiple doses
“There were no treatment‐related TEAEs in the Sex Effect Part 3 cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These observations suggest that a stimulus–response reaction to some of the study procedures was more plausible than a relationship to the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum potassium during multiple dosing
“Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment. There was a maximum mean increase of 0.44 mmol/L after 40 mg on Day 8, 0.6 mmol/L after 120 mg on Day 7, and 0.48 mmol/L after 360 mg on Day 6. None of the subjects reached the stopping criterion for potassium of 6.0 mmol/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon cessation of lorundrostat treatment, serum potassium levels rapidly fell toward pretreatment baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concentration-QTc results
Exposure margin and waiver of a thorough QT study
Heart rate, PR, and QRS intervals
Study limitations
Summary
MT-4129-E01 randomized 116 healthy white participants at one center in the Netherlands. Parts 1 and 2 enrolled men aged 18 to 55 years only, and the effects of sex and of age were each assessed in one cohort of 8 participants, 6 of whom received a single 100 mg dose. Multiple dosing lasted 7 days, so the study gives no information on longer treatment or on people with hypertension. Lorundrostat was given as a capsule whose exposure the authors state is about 50% of that of the tablet used in the phase 2 study, the comparison of fed and fasted pharmacokinetics was exploratory with no formal statistical comparison, and the formal tablet food effect study is described as “data on file”. The ClinicalTrials.gov record lists enrollment as estimated. The concentration-QTc analysis is reported in a congress poster by authors from Mineralys Therapeutics and Clario. The publication states that the studies it reports were funded by Mineralys Therapeutics, while the registry record names Tanabe Pharma Corporation as sponsor, and the authors include employees of Mitsubishi Tanabe Pharma Corporation, Mineralys Therapeutics, and ICON, the contract research organization that conducted the study.
Healthy male participants in the dose-escalation parts
“Oral administration of lorundrostat, either as single dose up to 800 mg under fasted conditions (SAD part 1) or as once‐daily dose up to 360 mg for 7 days under fed conditions (MAD part 2), was well tolerated with a favorable safety profile in a group of healthy male participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of sodium depletion not addressed
“Although the urinary electrolyte measurements confirmed that there was a brief period of natriuresis at all doses tested, the duration and stability of the sodium depletion is not addressed by that measurement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding and author affiliations
“All studies reported in this manuscript were funded by Mineralys Therapeutics, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hidetoshi Shimizu, Yoshiyasu Ohta, Kei Ogawa, Sheikh Mohammed Ashfaq Rahman, Aya Fujii, Yuki Hiraga, Mizue Kawai, and Kanami Sugimoto‐Kawabata are employees of Mitsubishi Tanabe Pharma Corporation, which invented and out‐licensed the compound to Mineralys Therapeutics, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Michael A. Tortorici, Stephen Djedjos, and David M. Rodman are employees of Mineralys Therapeutics, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote